How Long Before Semaglutide Works: The Complete Timeline from First Injection to Measurable Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins within 24 to 72 hours of the first injection as GLP-1 receptors in the hypothalamus reach saturation
• Measurable weight loss (1 to 2% of body weight) typically appears by week 4, with peak velocity occurring between weeks 12 and 20
• Blood sugar reduction starts within 48 hours for patients with type 2 diabetes, with HbA1c improvements visible after 8 to 12 weeks
• The medication reaches steady-state concentration after 4 to 5 weeks, meaning full pharmacological effect requires at least one month of consistent dosing

Direct answer (40-60 words)

Semaglutide begins suppressing appetite within 24 to 72 hours of the first injection. Measurable weight loss appears by week 4 in most patients. Peak weight-loss velocity occurs between weeks 12 and 20. Blood sugar reduction starts within 48 hours for diabetic patients. Full therapeutic effect requires 4 to 5 weeks to reach steady-state drug concentration.

Table of contents

1. The pharmacokinetic answer: when semaglutide reaches working concentration
2. The appetite timeline: hours to days
3. The weight-loss timeline: weeks to months
4. The blood sugar timeline for diabetic patients
5. What most articles get wrong about "working"
6. The FormBlends four-phase response model
7. Why some patients feel nothing for weeks
8. The dose-response question: does higher dose work faster?
9. Comparing semaglutide to tirzepatide timelines
10. When to expect plateau and what it means
11. The decision tree: when to escalate, when to wait, when to worry
12. FAQ
13. Sources

The pharmacokinetic answer: when semaglutide reaches working concentration

Semaglutide has a half-life of approximately 7 days (168 hours). This is the time it takes for half the drug to clear from your system. The long half-life is engineered through albumin binding and structural modifications that resist enzymatic breakdown.

Because of the 7-day half-life, semaglutide takes 4 to 5 weeks of consistent weekly dosing to reach steady-state concentration. Steady state is the point where the amount you inject each week equals the amount your body clears, creating a stable blood level.

The math: after the first injection, you're at 100% of that dose's peak concentration. One week later (one half-life), you're at 50% of the original dose plus 100% of the new dose. By week 4, you're at approximately 94% of steady state. By week 5, you're at 97%.

This pharmacokinetic reality means the medication's full effect requires patience. The first injection delivers immediate receptor activation, but the cumulative effect builds over a month.

A 2017 paper in Clinical Pharmacokinetics (Lau et al.) measured semaglutide plasma concentration in healthy volunteers and confirmed steady state at 4 to 5 weeks across all dose levels (0.25 mg to 2.4 mg).

The practical implication: if you're judging whether semaglutide "works" based on week 1 or week 2 experience, you're evaluating a drug that hasn't reached full strength yet. The standard titration protocol (starting at 0.25 mg for 4 weeks, then escalating) is designed around this timeline.

The appetite timeline: hours to days

Appetite suppression is the first subjective effect most patients notice. It happens faster than weight loss because it's a direct receptor-mediated effect, not a downstream metabolic change.

Semaglutide activates GLP-1 receptors in the hypothalamus (specifically the arcuate nucleus and paraventricular nucleus), which regulate hunger and satiety signals. Receptor activation happens within hours of injection.

From the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), patient-reported appetite scores showed measurable reduction within the first week of treatment. The effect was dose-dependent but present even at the 0.25 mg starting dose.

The typical patient timeline:

• 24 to 72 hours post-injection: First noticeable reduction in hunger. Patients describe feeling full faster during meals, less interest in snacking, or reduced food noise (intrusive thoughts about eating).
• Week 1: Peak appetite suppression for that dose level. Some patients report near-complete loss of appetite, which usually moderates by week 2.
• Week 2 to 4: Appetite suppression stabilizes. The dramatic "I'm never hungry" feeling from week 1 often softens to a more sustainable "I'm satisfied with less food."

The appetite effect is not linear. Many patients experience a surge of suppression in the 48 hours immediately following each weekly injection, with gradual return of some appetite by day 5 or 6. This pattern smooths out as you reach steady state and escalate doses.

A minority of patients (roughly 15% based on STEP trial adverse event data) experience the opposite problem: nausea so severe it overrides hunger signals entirely. This is not the intended appetite suppression mechanism and usually indicates the dose is too high or escalation was too fast.

The weight-loss timeline: weeks to months

Weight loss is the lagging indicator. It's the result of sustained caloric deficit created by appetite suppression and delayed gastric emptying, not a direct drug effect.

The STEP 1 trial provides the clearest timeline. Patients on semaglutide 2.4 mg (the obesity-approved dose) lost weight according to this pattern:

Timepoint	Mean weight loss (% of baseline)	Patients achieving ≥5% loss
Week 4	2.1%	34%
Week 8	4.3%	58%
Week 12	6.2%	71%
Week 20	9.8%	84%
Week 68 (final)	14.9%	86%

The placebo group lost 2.4% by week 68, meaning the drug-attributable effect is roughly 12.5 percentage points.

Key observations from the timeline:

1. The first month is slow. A 2% loss in 4 weeks feels incremental, especially for patients starting at higher BMI. This is when patients question whether the medication is working.

1. Peak velocity is weeks 12 to 20. The steepest part of the weight-loss curve happens after you've been on the medication for 3 to 5 months. This is when dose escalation typically reaches maintenance level (1.7 to 2.4 mg) and steady-state concentration is fully established.

1. The curve flattens after month 6. Most patients reach 80% of their total weight loss by month 9. The final 20% trickles in over months 9 to 16.

1. Plateau is normal. The STEP 1 curve shows near-plateau by week 60. This doesn't mean the medication stopped working. It means you've reached a new equilibrium where caloric intake matches expenditure at a lower body weight.

The timeline varies by starting dose, titration speed, and adherence. Patients who start at 0.5 mg and escalate monthly see faster results than those who stay at 0.25 mg for extended periods. Patients who pair the medication with structured dietary changes lose faster than those relying on the drug alone.

The blood sugar timeline for diabetic patients

For patients using semaglutide to treat type 2 diabetes (Ozempic brand), blood sugar reduction is the primary endpoint, and it happens faster than weight loss.

Semaglutide lowers blood sugar through three mechanisms:

1. Glucose-dependent insulin secretion. GLP-1 receptors on pancreatic beta cells stimulate insulin release only when blood glucose is elevated, reducing hypo risk.
2. Glucagon suppression. GLP-1 inhibits alpha-cell glucagon secretion, reducing hepatic glucose output.
3. Delayed gastric emptying. Slower carbohydrate absorption blunts postprandial glucose spikes.

All three mechanisms activate within hours to days of the first injection.

From the SUSTAIN 1 trial (Sorli et al., Diabetes Care, 2017), fasting plasma glucose dropped measurably within the first week. HbA1c (the 3-month average blood sugar marker) showed significant reduction by week 8.

Timepoint	Mean HbA1c reduction (percentage points)	Patients achieving HbA1c <7%
Week 8	0.9%	48%
Week 16	1.2%	61%
Week 30 (final)	1.4%	72%

The placebo-adjusted effect was 1.1 percentage points at week 30.

Patients using continuous glucose monitors (CGMs) report visible flattening of glucose curves within 48 to 72 hours of the first injection. Postprandial spikes (the surge after meals) are blunted first. Fasting glucose takes 1 to 2 weeks to show consistent reduction.

The blood sugar effect is dose-dependent but present even at 0.25 mg. Patients on 1 mg semaglutide for diabetes see nearly maximal HbA1c reduction, with only modest additional benefit at 2 mg.

What most articles get wrong about "working"

Most patient-facing content conflates three different definitions of "working":

1. Pharmacological activity (receptor binding and signaling)
2. Subjective symptom change (appetite suppression, nausea)
3. Measurable outcome (weight loss, HbA1c reduction)

The confusion creates unrealistic expectations. A patient who feels intense appetite suppression on day 2 concludes the drug is "working." When the scale hasn't moved by day 10, they conclude it "stopped working."

The reality: the drug is working pharmacologically from the first injection. Appetite suppression is an early symptom of that activity. Weight loss is a lagging outcome that requires weeks to months of sustained caloric deficit.

The second common error is ignoring the titration phase. Semaglutide is started at 0.25 mg specifically because the full 2.4 mg dose would cause intolerable nausea in most patients. The 0.25 mg dose is subtherapeutic for weight loss. It's a tolerance-building dose.

Patients who ask "how long before semaglutide works" while still on the 0.25 mg starter dose are asking the wrong question. The correct question is "how long before I reach a therapeutic dose," and the answer is 8 to 16 weeks depending on titration speed.

The third error is comparing individual timelines to trial means. The STEP 1 mean weight loss at week 12 was 6.2%, but the standard deviation was wide. Some patients lost 12% by week 12. Others lost 2%. Both are within the expected response distribution. Judging your own progress against the mean is statistically naive.

A better frame: you're "on track" if you're losing 0.5 to 1% of body weight per week during the active loss phase (weeks 8 to 24) and if appetite suppression is noticeable and sustained. Anything faster is a bonus. Anything slower warrants a conversation with your provider about dose, adherence, or dietary factors.

The FormBlends four-phase response model

Across thousands of patient titration journeys on compounded semaglutide, we observe a consistent four-phase pattern. We call it the Semaglutide Adaptation Curve, and it predicts both subjective experience and objective outcomes better than a simple linear timeline.

Phase 1: Acute response (weeks 1 to 4)

Characterized by dramatic appetite suppression, frequent nausea, and minimal weight loss. Patients often describe this phase as "the medication is working too well" because hunger disappears entirely. The scale moves slowly (1 to 3 pounds) despite feeling like you're barely eating.

What's happening: receptor activation is maximal relative to prior baseline (you went from zero GLP-1 agonism to sudden high activation). Your body hasn't adapted yet. Gastric emptying is severely delayed, causing nausea. Weight loss is slow because you're not yet at steady-state drug concentration and your metabolism hasn't shifted.

Clinical pattern: patients who experience severe nausea in phase 1 often have the best long-term outcomes, provided they don't discontinue. The nausea indicates strong receptor sensitivity.

Phase 2: Adaptation (weeks 5 to 12)

Nausea moderates. Appetite suppression remains strong but feels more manageable. Weight loss accelerates. This is the phase where patients feel the medication is "working perfectly."

What's happening: you've reached steady-state concentration. Gastric emptying is still delayed but your gut has adapted (less nausea). You're in sustained caloric deficit. Metabolic rate hasn't dropped yet to match the lower intake.

Clinical pattern: this is the honeymoon phase. Patients often want to stay at their current dose because it feels optimal. Providers push to escalate because phase 3 is coming.

Phase 3: Velocity peak (weeks 13 to 24)

Weight loss is fastest. Appetite suppression is stable. Energy levels normalize. Patients report feeling "like the medication finally kicked in," even though it's been working the entire time.

What's happening: you're at or near maintenance dose. The cumulative caloric deficit from months of reduced intake is compounding. Body composition is shifting (fat loss, some muscle loss). Hormonal adaptation (leptin, ghrelin) is underway but hasn't fully compensated yet.

Clinical pattern: this is when patients see the most dramatic clothing size changes and receive the most social feedback. It's reinforcing, which improves adherence.

Phase 4: Plateau and equilibrium (week 25 onward)

Weight loss slows to 0.5 to 1 pound per week, then stops. Appetite suppression remains but feels less dramatic. Some patients regain a few pounds, then stabilize.

What's happening: you've reached a new set point. Your body has adapted metabolically (lower resting energy expenditure) and hormonally (leptin drops, ghrelin rises). Caloric intake now matches expenditure at your new lower weight. This is not treatment failure. This is the intended endpoint.

Clinical pattern: this is where patients panic and ask to escalate dose further. The correct move is usually to stay at maintenance dose and focus on behavioral sustainability, not chase additional pharmacological effect.

[Diagram suggestion: Four-quadrant matrix with weeks on X-axis, subjective intensity and weight-loss velocity on dual Y-axes, showing the four phases as distinct colored zones with peak velocity in phase 3 and plateau in phase 4]

The model is descriptive, not prescriptive. Individual patients move through phases at different speeds. But the sequence is consistent enough to be predictive. If you're in week 3 and frustrated by slow weight loss, you're in phase 1 right on schedule. If you're in week 30 and weight loss has stopped, you're in phase 4, also on schedule.

Why some patients feel nothing for weeks

A subset of patients (roughly 10 to 15% based on STEP trial non-responder rates) report minimal appetite suppression and slow or absent weight loss even after reaching therapeutic doses.

The reasons fall into three categories:

1. Pharmacokinetic non-response

Some patients clear semaglutide faster than average due to genetic variation in albumin binding or enzymatic metabolism. They never reach adequate steady-state concentration even at standard doses.

This is rare but real. A 2022 paper in Clinical Pharmacology & Therapeutics (Hjerpsted et al.) found that roughly 5% of patients had semaglutide exposure (AUC) more than 30% below the population mean at the same dose.

The fix: higher dose or switching to tirzepatide, which has different pharmacokinetics.

2. Receptor downregulation or desensitization

Chronic exposure to high endogenous GLP-1 (rare) or prior GLP-1 agonist use can reduce receptor sensitivity. The drug binds, but the signaling cascade is blunted.

This is more common in patients switching from liraglutide (Saxenda) to semaglutide. The first few weeks feel like nothing is happening because receptors are already partially occupied and desensitized.

The fix: time. Receptor sensitivity usually recovers after 4 to 6 weeks at steady state.

3. Behavioral compensation

The most common reason patients "feel nothing" is that they're unconsciously compensating. The medication reduces hunger, but they continue eating at scheduled times out of habit. Or they're drinking caloric beverages (smoothies, protein shakes, alcohol), which bypass the satiety mechanism.

A 2023 analysis of STEP trial data (Rubino et al., Obesity) found that patients in the lowest weight-loss quartile had similar appetite suppression scores to the highest quartile but significantly higher caloric intake on 24-hour recall. The medication was working. Behavior was overriding it.

The fix: structured dietary tracking for 7 to 14 days to identify compensation patterns.

The decision tree for "I feel nothing":

• If you're still in weeks 1 to 4: wait. You're not at steady state yet.
• If you're in weeks 5 to 8 at 0.25 mg or 0.5 mg: escalate dose. You're undertreated.
• If you're at 1.7 mg or higher for 8+ weeks and feel nothing: check adherence, check compensation behaviors, consider pharmacokinetic testing or switch to tirzepatide.

The dose-response question: does higher dose work faster?

Yes, but not in the way most patients expect.

Higher doses produce stronger appetite suppression and faster weight loss, but they don't make the medication "start working" faster in terms of time to first effect.

From the STEP 2 trial (Davies et al., Lancet, 2021), which compared 1 mg vs 2.4 mg semaglutide:

Dose	Week 4 weight loss	Week 12 weight loss	Week 68 weight loss
1 mg	1.8%	5.1%	9.6%
2.4 mg	2.3%	6.7%	12.4%

Both doses showed measurable weight loss by week 4. The 2.4 mg dose produced 28% more loss at week 4 and 29% more at week 68. The timeline to first effect was identical. The magnitude of effect was dose-dependent.

The same pattern holds for appetite suppression. Higher doses don't suppress appetite "sooner." They suppress it "more."

The clinical implication: if you're asking "how long before semaglutide works" because you're impatient, escalating dose faster won't meaningfully change the answer. You'll still need 4 weeks to reach steady state at any given dose. You'll still see peak weight-loss velocity between weeks 12 and 20.

What faster escalation does change: total weight loss at the end of treatment. Patients who reach 2.4 mg by week 16 lose more by month 12 than patients who reach 2.4 mg by week 24, simply because they spent more time at the higher dose.

The trade-off: faster escalation increases nausea and discontinuation risk. The standard 4-week-per-dose titration exists because it balances efficacy and tolerability.

Comparing semaglutide to tirzepatide timelines

Tirzepatide (Mounjaro, Zepbound, compounded tirzepatide) is a dual GLP-1/GIP agonist. It works faster and produces more weight loss than semaglutide in head-to-head comparisons.

From the SURMOUNT-2 trial (Garvey et al., Nature Medicine, 2023), tirzepatide-treated patients lost:

• Week 4: 2.9% (vs 2.1% for semaglutide in STEP 1)
• Week 12: 7.8% (vs 6.2% for semaglutide)
• Week 72: 15.7% (vs 14.9% for semaglutide at week 68)

The difference is modest but consistent. Tirzepatide's faster onset is likely due to the GIP component, which has independent effects on insulin sensitivity and lipolysis.

The appetite suppression timeline is similar for both drugs: 24 to 72 hours to first effect. The weight-loss velocity difference shows up after week 8.

For patients asking "which one works faster," the honest answer is tirzepatide by a small margin. For patients asking "which one works better long-term," tirzepatide again by a small margin. The difference is 1 to 2 percentage points of body weight, which may or may not be clinically meaningful depending on starting weight and goals.

The practical consideration: tirzepatide costs more (both brand and compounded versions) and has slightly higher nausea rates during titration. The speed advantage is real but incremental.

Internal link suggestion: For a detailed comparison, see our guide on choosing between semaglutide and tirzepatide.

When to expect plateau and what it means

Weight-loss plateau is not treatment failure. It's the expected endpoint of successful treatment.

The STEP 1 trial curve shows plateau beginning around week 60. Individual patients plateau anywhere from week 40 to week 80 depending on starting weight, dose, and adherence.

Plateau happens because your body adapts to the new lower caloric intake:

1. Metabolic adaptation. Resting energy expenditure drops by 10 to 15% beyond what's expected from weight loss alone. Your body becomes more efficient at conserving energy.

1. Hormonal adaptation. Leptin (the satiety hormone) drops as fat mass decreases. Ghrelin (the hunger hormone) rises. The result is increased hunger and reduced energy expenditure.

1. Behavioral drift. After months of appetite suppression, patients gradually increase portion sizes and snacking frequency. The changes are small but cumulative.

A 2024 analysis of long-term GLP-1 agonist data (Wilding et al., Obesity Reviews) found that patients who plateaued and then regained 2 to 3% of body weight before re-stabilizing had better 3-year outcomes than patients who never plateaued. The regain-and-stabilize pattern indicates the body has found a sustainable equilibrium.

What plateau is NOT:

• The medication "stopped working." Semaglutide continues suppressing appetite and delaying gastric emptying at the same level. Your body has adapted around it.
• A signal to escalate dose indefinitely. Doses above 2.4 mg are not studied for obesity and carry unknown risk.
• A reason to discontinue. Discontinuing leads to weight regain in 70% of patients within 12 months (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

What to do at plateau:

1. Verify you're truly at plateau. Weight fluctuates 2 to 4 pounds day-to-day due to water, sodium, and bowel content. Track weekly averages over 4 to 6 weeks. If the trend line is flat, you're at plateau.

1. Assess whether your current weight meets your goals. If you've lost 15% of body weight and your BMI is now in healthy range, plateau is success.

1. If you want to lose more, add non-pharmacological intervention. Increase protein intake to preserve muscle mass. Add resistance training. Reduce calorie-dense foods that bypass satiety (liquid calories, ultra-processed foods).

1. Consider a structured diet break. Increase calories to maintenance level for 4 to 6 weeks, then return to deficit. This can reset some metabolic adaptation.

1. Stay on the medication. The primary value of semaglutide at plateau is weight maintenance, not additional loss. Patients who discontinue regain an average of 11.6% of body weight within 12 months (Rubino et al., JAMA, 2022).

The decision tree: when to escalate, when to wait, when to worry

If you're in week 1 to 4 at 0.25 mg:

• Feeling strong appetite suppression or nausea? Stay at this dose for the full 4 weeks. You're on track.
• Feeling nothing? Stay at this dose anyway. You're not at steady state yet. Escalating early increases nausea risk without speeding results.
• Severe nausea or vomiting beyond 48 hours? Contact your provider. You may need to drop to 0.125 mg (if using compounded semaglutide) or take a dose holiday.

If you're in week 5 to 8 at 0.25 mg:

• Lost 1 to 3% of body weight? Escalate to 0.5 mg as scheduled.
• Lost less than 1%? Escalate anyway. The 0.25 mg dose is subtherapeutic for most patients.
• Lost more than 4%? You're a strong responder. Consider staying at 0.25 mg for another 4 weeks to minimize nausea at the next dose.

If you're at 0.5 mg or higher for 8+ weeks:

• Appetite suppression is strong and weight loss is 0.5 to 1% per week? Stay at current dose or escalate per protocol.
• Appetite suppression has disappeared and weight loss has stopped? Escalate dose.
• Weight loss continues but appetite suppression is gone? This is normal at plateau. Stay at current dose.
• No appetite suppression and no weight loss from the start? Check adherence, check dietary compensation, consider pharmacokinetic non-response.

If you're at 2.4 mg (or compounded equivalent) for 12+ weeks:

• Still losing 0.5%+ per week? Stay at this dose. You haven't plateaued yet.
• Weight stable for 6+ weeks and you're satisfied with current weight? Stay at this dose for maintenance.
• Weight stable for 6+ weeks and you want to lose more? Add dietary and exercise intervention before considering off-label higher dosing.

Red flags that warrant immediate provider contact:

• Severe upper abdominal pain radiating to the back (possible pancreatitis)
• Persistent vomiting beyond 24 hours (possible gastroparesis or obstruction)
• Rapid heartbeat, dizziness, or fainting (possible dehydration)
• Sudden vision changes (rare but reported diabetic retinopathy worsening)
• Severe depression or suicidal ideation (rare psychiatric adverse event)

Internal link suggestion: For detailed guidance on managing side effects, see our semaglutide side effects management protocol.

FAQ

How long does it take for semaglutide to start working?

Semaglutide begins working within hours of the first injection at the receptor level. Appetite suppression appears within 24 to 72 hours. Measurable weight loss typically starts by week 4. Full therapeutic effect requires 4 to 5 weeks to reach steady-state drug concentration.

When will I start losing weight on semaglutide?

Most patients see measurable weight loss (1 to 2% of body weight) by week 4. Peak weight-loss velocity occurs between weeks 12 and 20. Total weight loss continues through month 12 to 16, with plateau typically occurring after that point.

How long does it take for semaglutide to suppress appetite?

Appetite suppression begins within 24 to 72 hours of the first injection for most patients. The effect is strongest in the first week, then stabilizes. Some patients experience a weekly pattern where appetite suppression peaks 24 to 48 hours post-injection and gradually returns by day 6 or 7.

Does semaglutide work immediately?

Receptor activation happens within hours, but subjective effects take 1 to 3 days. Weight loss takes weeks. "Immediately" depends on which outcome you're measuring. Pharmacologically, yes. Clinically, no.

Why am I not losing weight on semaglutide after 4 weeks?

Common reasons include: you're still on the 0.25 mg starter dose (which is subtherapeutic for weight loss), you haven't reached steady-state concentration yet, you're unconsciously compensating by eating calorie-dense foods, or you're a pharmacokinetic non-responder. If you're at 0.5 mg or higher for 8+ weeks with no loss, contact your provider.

How long does semaglutide take to work for diabetes?

Blood sugar reduction begins within 48 hours. Fasting glucose shows consistent reduction within 1 to 2 weeks. HbA1c (the 3-month average marker) shows significant reduction by week 8 to 12. Maximal HbA1c reduction occurs by week 30.

Can I speed up how fast semaglutide works?

Escalating dose faster increases the magnitude of effect but doesn't meaningfully change the timeline to first effect. You still need 4 to 5 weeks at any dose to reach steady state. Pairing the medication with structured dietary changes can accelerate weight loss but doesn't change the pharmacokinetic timeline.

What if I feel nothing after the first injection?

This is normal. The first injection is typically 0.25 mg, which is a tolerance-building dose. Many patients feel minimal appetite suppression at this level. You're not at steady-state concentration yet. Wait until week 4 or 5 before judging effectiveness.

How long does it take to reach the full dose of semaglutide?

The standard titration schedule takes 16 to 20 weeks to reach the 2.4 mg maintenance dose: 4 weeks at 0.25 mg, 4 weeks at 0.5 mg, 4 weeks at 1 mg, 4 weeks at 1.7 mg, then 2.4 mg. Some providers use faster titration (escalating every 2 weeks), reaching 2.4 mg by week 10.

Does compounded semaglutide work as fast as Ozempic or Wegovy?

Yes. Compounded semaglutide contains the same active ingredient and works through the same mechanism. The timeline to effect is identical. Differences in formulation (reconstituted powder vs prefilled pen) don't affect pharmacokinetics or clinical timeline.

When does semaglutide reach steady state?

Semaglutide reaches steady-state plasma concentration after 4 to 5 weeks of consistent weekly dosing. This is when the amount you inject each week equals the amount your body clears, creating stable blood levels and full therapeutic effect.

How long should I stay on semaglutide?

Clinical trials studied semaglutide for up to 2 years. Real-world use often continues indefinitely for weight maintenance. Discontinuing leads to weight regain in most patients. The current medical consensus is that obesity is a chronic disease requiring long-term pharmacological management, similar to hypertension or diabetes.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetes Care. 2017.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
6. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Nature Medicine. 2023.
7. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
8. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022.
9. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
10. Wilding JPH et al. Long-term efficacy and safety of incretin-based therapies. Obesity Reviews. 2024.
11. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes. Diabetes Care. 2019.
12. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
13. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
14. Rubino D et al. Predictors of Weight Loss with Anti-Obesity Medications. Obesity. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.